Das SRH Wald-Klinikum Gera ist ein Krankenhaus in Gera, in dem etwa 109.460 Patienten im Jahr ambulant und stationär behandelt werden. Die Einrichtung ist Akademisches Lehrkrankenhaus des Universitätsklinikums Jena und beschäftigt rund 1.800 Mitarbeiter.

During the past decade, SRH Wald-Klinikum Gera GmbH conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 17 clinical trials were completed, i.e. on average, 43.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 15 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SRH Wald-Klinikum Gera GmbH" #1 sponsor was "Biotronik SE & Co. KG" with 7 trials, followed by "Pfizer" with 6 trials sponsored, "LEO Pharma" with 3 trials sponsored, "Prof. Dr. med. Dirk Schadendorf" with 3 trials sponsored and "Journey Medical Corporation" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SRH Wald-Klinikum Gera GmbH" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Alcedis GmbH" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Biotronik, Inc." with 1 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "SRH Wald-Klinikum Gera GmbH" are "Heart Failure" (5 trials), "Melanoma" (5 trials), "Atopic Dermatitis" (4 trials), "Tachyarrhythmia" (4 trials) and "Atrial Fibrillation (AF)" (2 trials). Many other conditions were trialed in "SRH Wald-Klinikum Gera GmbH" in a lesser frequency.

Most popular intervention types in "SRH Wald-Klinikum Gera GmbH" are "Drug" (31 trials), "Device" (11 trials), "Other" (3 trials), "Biological" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Nivolumab" (3 trials), "Abrocitinib 200 mg" (2 trials), "MEK162" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "SRH Wald-Klinikum Gera GmbH" are 47 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "SRH Wald-Klinikum Gera GmbH". undefined are not yet recruiting, 5 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in SRH Wald-Klinikum Gera GmbH, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in SRH Wald-Klinikum Gera GmbH, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 9 trials that are defined as “Not Applicable".